These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18328146)

  • 1. Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy.
    Favalli EG; Marchesoni A; Colombo GL; Sinigaglia L
    Clin Exp Rheumatol; 2008; 26(1):45-51. PubMed ID: 18328146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.
    Ramírez-Herráiz E; Escudero-Vilaplana V; Alañón-Plaza E; Trovato-López N; Herranz-Alonso A; Morell-Baladrón A; Sanjurjo-Sáez M
    Clin Exp Rheumatol; 2013; 31(4):559-65. PubMed ID: 23710583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis.
    Ollendorf DA; Massarotti E; Birbara C; Burgess SM
    J Manag Care Pharm; 2005 Jun; 11(5):383-93. PubMed ID: 15934797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit.
    Sidiropoulos P; Bertsias G; Kritikos HD; Kouroumali H; Voudouris K; Boumpas DT
    Ann Rheum Dis; 2004 Feb; 63(2):144-8. PubMed ID: 14722202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
    Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
    J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis.
    Stern R; Wolfe F
    J Rheumatol; 2004 Aug; 31(8):1538-45. PubMed ID: 15290732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis.
    Benucci M; Stam WB; Gilloteau I; Sennfält K; Leclerc A; Maetzel A; Lucioni C
    Clin Exp Rheumatol; 2013; 31(4):575-83. PubMed ID: 23711100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice.
    Virkki LM; Konttinen YT; Peltomaa R; Suontama K; Saario R; Immonen K; Jäntti J; Tuomiranta T; Nykänen P; Hämeenkorpi R; Heikkilä S; Isomäki P; Nordström D
    Clin Exp Rheumatol; 2008; 26(6):1059-66. PubMed ID: 19210870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
    Flendrie M; Creemers MC; van Riel PL
    Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.
    Durez P; Van den Bosch F; Corluy L; Veys EM; De Clerck L; Peretz A; Malaise M; Devogelaer JP; Vastesaeger N; Geldhof A; Westhovens R
    Rheumatology (Oxford); 2005 Apr; 44(4):465-8. PubMed ID: 15695306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
    Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Breedveld FC; Dijkmans BA;
    Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose intensification with infliximab in patients with rheumatoid arthritis.
    Berger A; Edelsberg J; Li TT; Maclean JR; Oster G
    Ann Pharmacother; 2005 Dec; 39(12):2021-5. PubMed ID: 16288073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
    Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
    J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study.
    Gilbert TD; Smith D; Ollendorf DA
    BMC Musculoskelet Disord; 2004 Oct; 5(1):36. PubMed ID: 15485582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Costs of biological treatment of rheumatoid arthritis].
    Rasmussen C; Knudsen MS; Hansen BB; Lindkvist RM
    Ugeskr Laeger; 2009 May; 171(19):1585-90. PubMed ID: 19419639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.